The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Findings of a Phase I study of anitocabtagene autoleucel for the treatment of R/R myeloma
Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, presents the long-term follow-up of a Phase I first-in-human dose escalation study (NCT04155749) of anitocabtagene autoleucel (anito-cel), a novel CAR T-cell product, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Dhakal highlights this product’s unique characteristics, enabling it to demonstrate promising clinical activity in a highly challenging patient population in which all patients were triple-class refractory and over two-thirds were penta-refractory. The encouraging efficacy and manageable safety profile demonstrated in this study have led to the development of Phase II and III trials to further investigate anito-cel. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
